全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Acute Renal Failure and Jaundice without Methemoglobinemia in a Patient with Phenazopyridine Overdose: Case Report and Review of the Literature

DOI: 10.1155/2014/845372

Full-Text   Cite this paper   Add to My Lib

Abstract:

Phenazopyridine is a commonly used urinary analgesic available throughout the United States. Ingestion of large quantities can lead to methemoglobinemia, hemolytic anemia, jaundice, and acute renal failure. We report a case of a 78-year-old male with previously normal renal function who developed acute renal failure and jaundice without methemoglobinemia or hyperbilirubinemia after taking nearly 8?g of phenazopyridine over the course of 4 days. Initially presenting with oliguria, the urine output began to increase by day 2 of his admission, and the creatinine peaked 11 days after he began taking phenazopyridine, and he was discharged safely soon after. To our knowledge, this is the first such case of renal failure and jaundice without methemoglobinemia or hemolytic anemia in an adult patient with normal renal function. 1. Introduction Phenazopyridine is a commonly prescribed urinary analgesic which has been in use since the 1920s [1]. Its use is associated with gastrointestinal discomfort and orange discoloration of urine [2]. Rarely, patients have developed pigment stones due to the red azo dye which is part of the drug’s formulation [1]. In large doses, phenazopyridine has been reported to cause renal failure, methemoglobinemia, skin pigmentation, and hemolytic anemia [2–7]. These findings often occur together, although isolated renal failure has been reported in pediatric patients and in patients with underlying renal disease [4, 7, 8]. We report a case of anuric renal failure and jaundice due to phenazopyridine without hyperbilirubinemia, methemoglobinemia, or hemolytic anemia in a patient without underlying renal disease. Previous case reports of phenazopyridine-associated kidney injury have either been in pediatric patients or in patients with underlying renal disease; to our knowledge, this is the first such case in a patient with normal renal function [3]. 2. Case Report A 78-year-old male physician with no prior renal disease presented to the emergency department with anuria. Five days prior to presentation, he had developed dysuria and urinary frequency and started himself on levofloxacin and phenazopyridine. Over the course of four days, he had taken 39 200?mg tabs of phenazopyridine (approximately 7.8?g). One day prior to admission, he noted that his urine output had ceased despite increased oral intake and decided to present to the emergency department. On presentation, the patient was hypotensive to 70/40 with a heart rate of 91?bpm but had no orthostatic symptoms. He received four liters of normal saline with no improvement in urine

References

[1]  E. D. Green, R. C. Zimmerman, W. H. Ghurabi, and D. P. Colohan, “Phenazopyridine hydrochloride toxicity: a cause of drug-induced methemoglobinemia,” Journal of the American College of Emergency Physicians, vol. 8, no. 10, pp. 426–431, 1979.
[2]  A. M. Onder, V. Espinoza, M. E. Berho, J. Chandar, G. Zilleruelo, and C. Abitbol, “Acute renal failure due to phenazopyridine (Pyridium) overdose: case report and review of the literature,” Pediatric Nephrology, vol. 21, no. 11, pp. 1760–1764, 2006.
[3]  F. A. Alano Jr. and G. D. Webster Jr., “Acute renal failure and pigmentation due to phenazopyridine (Pyridium),” Annals of Internal Medicine, vol. 72, no. 1, pp. 89–91, 1970.
[4]  D. A. Feinfeld, R. Ranieri, H. I. Lipner, and M. M. Avram, “Renal failure in phenazopyridine overdose,” Journal of the American Medical Association, vol. 240, no. 24, p. 2661, 1978.
[5]  E. P. Gabor, L. Lowenstein, and N. K. M. de Leeuw, “Hemolytic anemia induced by phenylazo-diamino-pyridine (Pyridium),” Canadian Medical Association Journal, vol. 91, no. 14, pp. 756–759, 1964.
[6]  D. M. Nathan, A. J. Siegel, and H. F. Bunn, “Acute methemoglobinemia and hemolytic anemia with phenazopyridine. Possible relation to acute renal failure,” Archives of Internal Medicine, vol. 137, no. 11, pp. 1636–1638, 1977.
[7]  D. B. Scheurer, “An over-the-counter omission,” Southern Medical Journal, vol. 99, no. 9, pp. 1005–1006, 2006.
[8]  M. E. Fincher and H. T. Campbell, “Methemoglobinemia and hemolytic anemia after phenazopyridine hydrochloride (pyridium) administration in end-stage renal disease,” Southern Medical Journal, vol. 82, no. 3, pp. 372–374, 1989.
[9]  W. J. Johnson and A. Chartrand, “The metabolism and excretion of phenazopyridine hydrochloride in animals and man,” Toxicology and Applied Pharmacology, vol. 37, no. 2, pp. 371–376, 1976.
[10]  B. H. Thomas, L. W. Whitehouse, G. Solomonraj, and C. J. Paul, “Excretion of phenazopyridine and its metabolites in the urine of humans, rats, mice, and guinea pigs,” Journal of Pharmaceutical Sciences, vol. 79, no. 4, pp. 321–325, 1990.
[11]  R. P. Walton and E. H. Lawson, “Pharmacology and toxicology of the azo dye, phenyl-azo-alpha-alpha-diaminopyridine (Pyridium),” Journal of Pharmacology and Experimental Therapeutics, vol. 51, no. 2, pp. 200–216, 1934.
[12]  R. E. Sand and C. M. Edelmann Jr., “Pyridium-induced methemoglobinemia: report of a case,” The Journal of Pediatrics, vol. 58, no. 6, pp. 845–848, 1961.
[13]  S. M. Bradberry, “Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue,” Toxicological Reviews, vol. 22, no. 1, pp. 13–27, 2003.
[14]  J. W. Hood and W. N. Toth, “Jaundice caused by phenazopyridine hydrochloride,” The Journal of the American Medical Association, vol. 198, no. 13, pp. 1366–1367, 1966.
[15]  R. Munday and E. Manns, “2, 3, 6-triaminopyridine, a metabolite of the urinary tract analgesic phenazopyridine, causes muscle necrosis and renal damage in rats,” Journal of Applied Toxicology, vol. 18, no. 2, pp. 161–165, 1998.
[16]  M. S. Greenberg, “Heinz body hemolytic anemia. “Bite cells”—a clue to diagnosis,” Archives of Internal Medicine, vol. 136, no. 2, pp. 153–155, 1976.
[17]  P. C. J. Ward, B. S. Schwartz, and J. G. White, “Heinz-body anemia: “bite cell” variant—a light and electron microscopic study,” American Journal of Hematology, vol. 15, no. 2, pp. 135–146, 1983.
[18]  B. Tomlinson, S. L. Cohen, M. R. Smith, and C. Fisher, “Nephrotoxicity of phenazopyridine,” Human & Experimental Toxicology, vol. 2, no. 3, pp. 539–543, 1983.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413